Interview: BioInvent and CASI on their collaboration
June 22, 2022
In a BioStock Studio exclusive, Martin Welschof, CEO of BioInvent and Wei-Wu He, Chairman and CEO of the American biopharma company CASI Pharmaceuticals, joined the program to talk about the collaboration between the two companies around the development of drug candidate BI-1206. Among other things, they discussed the reasons behind CASI choosing to partner with BioInvent, the market potential for BI-1206 and the next clinical development step for the candidate. Full Article & Video :
You May Also Like
CASI Pharmaceuticals to Report Third Quarter 2024 Financial Results.
CASI Pharmaceuticals Announces Second Quarter 2024 Business and Financial Results
CASI Pharmaceuticals Announces First Quarter 2024 Business and Financial Results